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Edited by Robert BaroukiAbstract Adipocyte-derived factors might play a role in the
development of hepatic insulin resistance. Resistin was identiﬁed
as an adipokine linking obesity and insulin resistance. Resistin is
secreted from adipocytes in rodents but in humans it was pro-
posed to originate from macrophages and its impact for insulin
resistance has remained elusive. To analyze the role of adipo-
kines in general and resistin as a special adipokine, we cultured
the human liver cell line HepG2 with adipocyte-conditioned med-
ium (CM) containing various adipokines such as IL-6 and MCP-1,
and resistin. CM and resistin both induce insulin resistance with
a robust decrease in insulin-stimulated phosphorylation of Akt
and GSK3. Insulin resistance could be prevented by co-treatment
with troglitazone but not by co-stimulation with adiponectin. As
human adipocytes do not secrete resistin, HepG2 cells were also
treated with resistin added into CM. CM with resistin addition
induced stronger insulin resistance than CM alone pointing to
a speciﬁc role of resistin in the initiation of hepatic insulin resis-
tance in humans.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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diabetes1. Introduction
Obesity is a major risk factor for insulin resistance and type
2 diabetes mellitus. Although this association is well estab-
lished, the underlying mechanisms have not been fully eluci-
dated. It has been demonstrated that adipose tissue can be
regarded as a major secretory and endocrine organ, and a vari-
ety of factors released by adipose cells potentially mediate
insulin resistance [1,2]. TNFa, leptin, adiponectin, MCP-1, res-
istin and several other adipokines are thought to be involved in
the regulation of insulin sensitivity.
Resistin, also known as adipocyte-secreted factor and Fizz3
[3,4], has been postulated to link obesity and insulin resistance
[5]. Current research revealed that the secretion of resistin
occurs diﬀerently in humans (macrophages) and in rodents
(adipocytes) [6,7]. The precise role of this factor for human
insulin resistance has remained elusive.*Corresponding author.
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doi:10.1016/j.febslet.2007.07.076The liver is a central metabolic organ and bifunctional in
glucose metabolism, namely glucose utilization and produc-
tion. Hepatic insulin resistance is presumed to be primarily
responsible for the development of type 2 diabetes [8]. Current
in vivo studies in rodents indicate that infusion of resistin
dramatically increases glucose production and impairs insulin
action in the liver, whereas its speciﬁc anti-sense oligodeoxynu-
cleotide reverses these eﬀects [9]. This suggests that resistin
may directly impair insulin action in the liver and that it might
exert speciﬁc functions in addition to adipocyte-derived fac-
tors.
In this study, we tested the hypothesis that the cross-talk
between fat and liver impairs insulin action in hepatocytes.
Using conditioned medium from in vitro diﬀerentiated human
adipocytes, we addressed the following questions: (1) whether
adipocyte-conditioned medium (CM) disturbs insulin signaling
in hepatic cells, (2) whether resistin can induce insulin resis-
tance in hepatocytes and (3) whether addition of resistin to
CM has an additive eﬀect.2. Materials and methods
2.1. Materials
Bovine serum albumin (BSA, fraction V, fatty acid free) was ob-
tained from Roth (Karlsruhe, Germany). Reagents for SDS–PAGE
were supplied by Amersham-Pharmacia Biotech (Braunschweig, Ger-
many) and by Sigma (Mu¨nchen, Germany). All primary antibodies
were supplied by Cell Signaling Technology (Frankfurt, Germany).
HRP-conjugated goat anti-rabbit and anti-mouse IgG antibodies were
from Promega (Mannheim, Germany). Culture media were obtained
from Gibco (Berlin, Germany). All other chemicals were of the highest
analytical grade commercially available and were purchased from Sig-
ma. The recombinant human resistin and full length adiponectin were
products from Tebu (Oﬀenbach, Germany).2.2. Adipocyte isolation and culture
Adipose tissue samples were obtained from the mammary fat of nor-
mal weight women undergoing surgical mammary reduction. This
gives access to large quantities of adipocytes needed for the generation
of conditioned media. All subjects were healthy, free of medication,
and had no evidence of diabetes according to routine laboratory tests.
Preadipocytes were isolated by collagenase digestion as previously
described by us [10]. The purity of adipocytes in the culture was ana-
lyzed by morphological means as described before [11]. These cells
were then used for generation of adipocyte-conditioned medium, as re-
cently described by us [12]. Brieﬂy, after in vitro diﬀerentiation, adipo-
cytes were incubated for 48 h in a-MEM containing 10 pM insulin.
This conditioned medium was then harvested and frozen for future
use.blished by Elsevier B.V. All rights reserved.
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HepG2 cells were grown in RPMI 1640 medium supplemented with
10% fetal bovine serum, 1% antibiotic–antimycotic mix and 1% neo-
mycin at 5% CO2 and 37 C.2.4. Immunoblotting
HepG2 cells were lysed in a buﬀer containing 50 mM Tris/HCl (pH
7.4), 1% (v/v) NP-40, 0.25% (v/v) sodium-deoxycholate, 150 mM
NaCl, 1 mM EGTA, 1 mM Na3VO4, and complete protease inhibitor
cocktail from Roche Diagnostics. After incubation for 2 h at 4 C, the
suspension was centrifuged at 10000 · g for 10 min. Thereafter, 10 lg
of lysates was separated by SDS–PAGE using 10% horizontal gels and
transferred to polyvinylidene ﬂuoride (PVDF) ﬁlters in a semidry blot-
ting apparatus [13]. For detection, ﬁlters were blocked with TBS con-
taining 0.1% Tween 20 and 5% non-fat dried milk and subsequently
incubated overnight with a 1:1000 dilution of appropriate antibodies.
After extensive washing, ﬁlters were incubated with secondary HRP-
coupled antibody and processed for enhanced chemiluminescence
(ECL) detection using Uptilight substrate (Interchim, France). Signals
were visualized and evaluated on a LUMI Imager workstation using
image analysis software (Boehringer-Mannheim, Mannheim,
Germany).2.5. ELISA for resistin
Resistin in adipocyte-conditioned medium was quantiﬁed using an
ELISA kit (BioVendor Laboratory Medicine, Inc.). The assay was per-
formed as recommended by the manufacturer using duplicate samples
for all determinations.2.6. Presentation of data and statistics
Statistical analysis was performed by ANOVA (Bonferroni post
hoc-test). All statistical analyses were done using Prism (GraphPad,
San Diego, CA) statistical software considering a P value of less than
0.05 statistically signiﬁcant. Corresponding signiﬁcance levels are indi-
cated in the ﬁgures.Fig. 1. Eﬀect of adipocyte-conditioned medium (CM) on phosphor-
ylation of Akt and GSK3 in HepG2 cells. HepG2 cells were subjected
to culture in the absence or presence of CM for 24 h and were
subsequently stimulated with insulin (100 nM, 5 min). Total cell
lysates (10 lg/lane) were resolved by SDS–PAGE and immunoblotted
with phosphospeciﬁc Akt and GSK3 (p-Akt and p-GSK3) and
tubulin antibodies. Western blots were quantiﬁed on a LUMI Imager
workstation using image analysis software. All data were normalized
to tubulin protein expression and expressed relative to the insulin-
stimulated control value. Data are means ± S.E.M. of three indepen-
dent experiments. *Signiﬁcantly diﬀerent from insulin-stimulated
control (P < 0.05).3. Results
3.1. Adipocyte-conditioned medium (CM) induces insulin
resistance in HepG2 cells
HepG2 cells were cultured with CM or the respective control
medium for 24 h to investigate the eﬀect of adipose-derived
factors on insulin signaling in hepatocytes. As presented in
Fig. 1, an up to 27 ± 4% and 30 ± 8% decrease in insulin-stim-
ulated serine phosphorylation of Akt and GSK3a/b, respec-
tively, was observed. It should be noted that the level of Akt
and GSK3 expression was not aﬀected by this treatment (data
not shown).
Troglitazone and adiponectin were tested together with CM
in order to investigate if these compounds may prevent insulin
resistance. When added for 24 h in the absence of CM, troglit-
azone slightly but not signiﬁcantly sensitized the HepG2 cells
towards insulin, with a 15% increase in the eﬀect of phosphor-
ylation of Akt (Fig. 2A). Addition of troglitazone to the CM
completely prevented the perturbation of insulin signaling at
the level of Akt phosphorylation (Fig. 2A). In contrast, adipo-
nectin was not able to prevent CM-induced insulin resistance
(Fig. 2B).3.2. Resistin impairs insulin sensitivity in HepG2 cells
The role of resistin in the development of insulin resistance
was assessed by culturing HepG2 cells for 24 h in the presence
of diﬀerent concentrations of this cytokine. Direct addition of
resistin to HepG2 cells was found to reduce the phosphoryla-
tion of Akt and GSK3 and showed a dose-dependent eﬀect(Fig. 3). The inhibitory eﬀect on Akt phosphorylation reached
signiﬁcance at 50 ng/ml resistin whereas GSK3 inhibition is
already signiﬁcantly impaired at 10 ng/ml resistin. Protein
expressions of Akt and GSK3 remained unaﬀected by resistin
stimulation (data not shown).
Fig. 2. Eﬀect of troglitazone and adiponectin on CM-induced insulin resistance in HepG2 cells. HepG2 cells were cultured in the absence or presence
of CM and 5 mM troglitazone (A) or 5 nM full length adiponectin (B) for 24 h and were subsequently stimulated with insulin (100 nM, 5 min). Total
cell lysates (10 lg/lane) were resolved by SDS–PAGE and immunoblotted with phosphospeciﬁc Akt (p-Akt) and tubulin antibodies. Western blots
were quantiﬁed on a LUMI Imager workstation using image analysis software. All data were normalized to tubulin protein expression and expressed
relative to the insulin-stimulated control value. Data are means ± S.E.M. of three independent experiments. *Signiﬁcantly diﬀerent from insulin-
stimulated control (P < 0.05), #signiﬁcantly diﬀerent from insulin-stimulated CM group (P < 0.05).
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eﬀects on insulin resistance induced by resistin. Troglitazone
completely prevents resistin-induced insulin resistance
(Fig. 4A). However, adiponectin could not restore hepatic
insulin sensitivity (Fig. 4B). These data indicate that resistin
is able to mimic the eﬀect of CM on insulin signaling in HepG2
cells.3.3. Adipocytes are not the main source for human resistin
The strong eﬀect of resistin on insulin signaling in hepato-
cytes makes it likely that resistin could represent a major adi-
pocyte-derived mediator of insulin resistance. To further
address this issue, resistin concentrations in CM were mea-
sured using an ELISA assay. Very low levels of resistin
(0.088 ± 0.003 ng/ml, n = 6) close to the detection limits of
the assay were detected in CM in accordance with earlier work
[14] and the literature that describes macrophages as the pri-
mary site of resistin secretion in human adipose tissue [7].3.4. Resistin addition to CM increases hepatic insulin resistance
Considering that human adipocytes do not secrete resistin
and that both resistin and CM have strong inhibitory eﬀects
on insulin sensitivity, we investigated whether addition of res-
istin to CM inﬂuences its eﬀect on hepatic insulin resistance.
We cultured HepG2 cells with 50 ng/ml resistin added to
CM. In cells treated with CM only, phosphorylation of Akt
was decreased by 44 ± 8% (P < 0.05 compared to control)
and phosphorylation of GSK3 was decreased by 21 ± 3%
(P < 0.05 compared to control). When HepG2 cells were trea-
ted with resistin added into CM, phosphorylation of Akt was
decreased by 58% ± 5% (P < 0.05 compared to CM alone) and
phosphorylation of GSK3 was decreased by 51 ± 10%(P < 0.05 compared to CM alone). Thus, resistin addition to
CM further deteriorates insulin signaling in hepatocytes.4. Discussion
The association between obesity, insulin resistance, and type
2 diabetes mellitus is well established; however, the mecha-
nisms of this association remain unclear. Several groups pro-
vided strong evidence to support the concept of adipose
tissue as an endocrine organ producing adipokines which mod-
ulate glucose homeostasis and insulin sensitivity [15]. Increas-
ing evidence indicates that dysfunction of adipose tissue
plays a crucial role in the development of insulin resistance
and type 2 diabetes.
Liver, as an important glucose metabolizing organ, plays a
key role in insulin resistance in diabetic patients. Based on
the assumption that increased adipokines may impair hepatic
insulin sensitivity, we investigated the eﬀect of adipocyte-con-
ditioned medium (CM) on hepatic insulin signaling by moni-
toring the insulin-dependent activation of Akt and GSK3.
Our data show that CM markedly inhibited phosphorylation
of Akt and GSK3. This result indicates that adipokines have
a potential role in the development of hepatic insulin resis-
tance.
Resistin was originally described as a link between obesity
and insulin resistance in rodents; however, its role has
remained somewhat controversial in humans [16]. Existing evi-
dence indicates that resistin inhibits insulin-dependent glucose
transport and mediates increased blood glucose level and hepa-
tic glucose production [17,18]. To investigate the role of resi-
stin in hepatic insulin resistance, diﬀerent concentrations of
resistin were used to treat hepatic cells and monitor the phos-
Fig. 3. Eﬀect of resistin on phosphorylation of Akt and GSK3 in
HepG2 cells. HepG2 cells were cultured with diﬀerent concentrations
of resistin for 24 h and were subsequently stimulated with insulin
(100 nM, 5 min). Total cell lysates (10 lg/lane) were resolved by SDS–
PAGE and immunoblotted with phosphospeciﬁc Akt, GSK3 (p-Akt,
p-GSK3) and tubulin antibodies. Western blots were quantiﬁed on a
LUMI Imager workstation using image analysis software. All data
were normalized to tubulin protein expression and expressed relative to
the insulin-stimulated control value. Data are means ± S.E.M. of three
independent experiments. *(P < 0.05) signiﬁcantly diﬀerent from insu-
lin-stimulated control.
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istin suppresses phosphorylation of Akt and GSK3 in a dose-
dependent manner. In another study, conditioned medium
from adipose-derived macrophages containing high levels of
resistin increased basal Akt phosphorylation [7]. We did notobserve an eﬀect of resistin treatment on basal Akt phosphor-
ylation so that this eﬀect may be due to other adipokines such
as visfatin secreted from macrophages. The resistin-induced
eﬀect on insulin signaling was similarly found in pancreatic
islets [19].
In rodents, resistin is primarily expressed in adipocytes.
Increased resistin levels impair glucose tolerance and induce
hepatic insulin resistance in vivo [20]. In humans, a more pro-
inﬂammatory function has been deﬁned for resistin [21,22].
Although some studies have reported resistin protein expres-
sion and secretion from human adipocytes [23,24], resistin gene
expression is accepted to be largely conﬁned to macrophages
[6,7,25]. We can conﬁrm this diﬀerential pattern of resistin
expression and secretion between humans and rodents by dem-
onstrating that primary human adipocytes do not secrete resi-
stin.
In the liver, adiponectin decreases hepatic glucose produc-
tion [26] and reduces free fatty acid turnover [27]. Troglitazone
improves insulin sensitivity and reverses insulin resistance [28–
30]. In this study, we could show that troglitazone could
reverse the eﬀects of CM or resistin on insulin signaling in
HepG2 cells. Adiponectin, on the other hand, was not able
to prevent insulin resistance induced by CM or resistin.
Recent investigations revealed that adipose tissue in obesity
is characterized by a chronic low-grade inﬂammatory state
[31]. Furthermore, it has been demonstrated that with increas-
ing adiposity there is profound macrophage inﬁltration into
adipose tissue. In both humans and rodents, macrophages
accumulate in adipose tissue with increasing body weight
and disappear again with weight loss [32,33].
Macrophage activation leads to two separate polarization
states, M1 and M2 [34,35]. M1 macrophages display en-
hanced proinﬂammatory cytokine production. Very recent
data suggest that in obesity circulating level of M1 macro-
phage are increased and contribute to their inﬁltration into
adipose tissue to replace M2 macrophages [36]. Resistin acts
as a proinﬂammatory cytokine in humans and is primarily
secreted by macrophages. Addition of resistin to CM of hu-
man adipocytes that is devoid of resistin may therefore rep-
resent a good model for the cytokine output from expanded
adipose tissue. In HepG2 cells, this combination induces
stronger insulin resistance than CM alone pointing to a role
of adipose tissue located macrophage contribution to insulin
resistance.
Recently, it has been reported that co-culture of hepatocytes
with fat cells induces hepatic insulin resistance and it was sug-
gested that TNFa and IL6 play a key role in this process [37].
In contrast, we demonstrate here that resistin and conditioned
medium from primary human adipocytes induces insulin resis-
tance in HepG2 cells. Addition of resistin to conditioned med-
ium further inhibits insulin signaling. Co-treatment with
troglitazone prevents insulin resistance in hepatocytes. More-
over, our former data indicated that human adipocytes do
not secrete TNFa [14] suggesting that TNFa plays diﬀerent
roles in rodents and humans. Many studies revealed that there
are increased resistin levels in obese and diabetic patients
[23,38,39]. Considering our data, we suggested that in humans,
obesity increases adipokine production which may impair
hepatic insulin sensitivity. Further, obesity also increases M1
macrophage inﬁltration into adipose tissue leading to
increased resistin levels which may additionally increase insulin
resistance in the liver.
Fig. 4. Eﬀect of troglitazone and adiponectin on resistin-induced insulin resistance in HepG2 cells. Insulin resistance in HepG2 cells was induced by
treatment with 50 ng/ml resistin for 24 h. Control cells and resistin-treated cells were co-treated with 5 mM troglitazone (A) or 5 nM full length
adiponectin (B). After insulin stimulation (100 nM, 5 min), total cell lysates (10 lg/lane) were resolved by SDS–PAGE and immunoblotted with
phosphospeciﬁc Akt (p-Akt) and tubulin antibodies. Western blots were quantiﬁed on a LUMI Imager workstation using image analysis software.
All data were normalized to tubulin protein expression and expressed relative to the insulin-stimulated control value. Data are means ± S.E.M. of
three independent experiments. *Signiﬁcantly diﬀerent from insulin-stimulated control (P < 0.05), #signiﬁcantly diﬀerent from insulin-stimulated
resistin group (P < 0.05).
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